Industry Sponsored Symposia

Sunday, May 22, 2016

13:30-15:00

Hall D ........ Fresenius Medical Care
Hall E ........ Vifor Fresenius Medical Care Renal Pharma
Hall B ........ B.Braun
Hall C ........ Baxter Healthcare
Hall G ........ Alexion Pharma International
Hall K ........ Chiesi Farmaceutici
Lounge 3 ...Shire International
Hall N ........ Immunodiagnostic Systems & Natto Pharma

18:45-19:45

Hall G ........ Merck Sharp & Dohme
Hall K ........ Amgen
Hall N ........ Bayer

Monday, May 23, 2016

13:30-15:00

Hall D ........ Baxter Healthcare
Hall E ........ Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance
Hall F ........ Otsuka Pharmaceutical Europe
Hall B ........ Vifor Fresenius Medical Care Renal Pharma
Hall C ........ Astra Zeneca
Hall G ........ Sanofi Genzyme
Hall K ........ Novartis Pharma
Hall M ........ NxStage Medical
Hall N ........ Raptor Pharmaceuticals

Tuesday, May 24, 2016

12:15-13:15

Hall K ........ Sigma-Tau
Personalized and Precise Renal Replacement Therapy

Improving Intradialytic Stability:
How to reduce the risk of extracorporeal thrombotic events.
Professor Martin Kuhlmann (Germany)

Cardiovascular Protection:
How to balance benefit/risk by fluid and electrolytes management.
Assoc. Professor Daniel Schneditz (Austria)

Uremic Toxicity, Gut-Kidney Axis and Renal Replacement Therapy:
How to improve outcome of advanced CKD patients by a multi-targeted approach.
Professor Griet Glorieux (Belgium)

May 22nd, 2016, 13:30-15:00
at the 53rd ERA-EDTA Congress, Vienna

Venue: Hall D, Austria Center Vienna
Dear Colleague,

It gives us great pleasure to welcome you to this Vifor Fresenius Medical Care Renal Pharma-sponsored symposium, entitled Protecting heart, vessels and bone – new ways to control phosphorus and potassium.

This educational programme offers insight from an international panel of experts, initially discussing the challenges faced in achieving phosphate control in haemodialysis patients and aspects that should be considered for optimizing management. Our second presentation looks at recent advances in hyperphosphataemia treatment, primarily focusing on iron-based, calcium-free phosphate binders that may offer a lower pill burden than previous treatments, thereby overcoming the challenge of patient non-adherence. Finally, we provide an overview of emerging therapies for hyperkalaemia that are suitable to use concomitantly with RAAS inhibitors in patients with chronic kidney disease.

This promises to be an engaging and informative programme and we encourage you to submit your questions for the Q&A session by completing the question cards provided and handing them to an organizer during the symposium.

Professor Markus Ketteler
Chair

Professor Alexander Rosenkranz
Co-Chair

Vifor Fresenius Medical Care Renal Pharma Ltd has fully sponsored this symposium and worked with the speakers on choice of topic and content. Payment has been made to the congress organizer to hold the symposium and lunch boxes have been provided by the company.
SUNDAY 22 MAY 2016
Time: 13:30 - 15:00
Hall B

PROGRAM & SPEAKERS

“Tailor-made hemodialysate composition – effects on hemodynamic stability”
Francesco Locatelli, Lecco, IT

“Convection volume in HDF – lessons learned for daily practice”
Peter J. Blankestijn, Utrecht, NL

“Renal dose achievement in AKI – influential factors”
Antoine Schneider, Lausanne, CH

CHAIR
Joachim Hoyer, Marburg, GER
Uremic toxins: urea, $\beta_2$-microglobulin and beyond

**Scientific Chair and Faculty**
Peter Stenvinkel, Stockholm, Sweden

**Faculty**
Muriel Grooteman, Amsterdam, The Netherlands
Colin Hutchison, Hawke’s Bay, New Zealand

**Industry Symposium**
13:30–15:00, Sunday 22 May 2016
Hall C, Level 2 (red level)
Austria Center Vienna

**Lunch will be provided**

**Agenda**
Sunday 22 May 2016
Program start time: 13:45
Program duration: one hour

**Program**
Introductions and welcome
From low-flux HD to high-flux and HDF: what’s next?
Uremic toxins beyond $\beta_2$m: what role do they play?
Albumin removal by dialysis: is there reason to be concerned?
Panel discussion and Q&A
Summary and close

Baxter Healthcare SA, Thurgauerstrasse 130, Glattpark, 8152, Switzerland
www.baxter.com

With the support of Baxter Healthcare SA
Dear Colleagues,

It is our pleasure to invite you to attend the Alexion-sponsored satellite symposium at the 53rd European Renal Association–European Dialysis and Transplant Association congress.

TMA: multiple causes for a disease with 100 faces?

The prognosis for patients with thrombotic microangiopathy (TMA) has evolved with the understanding of the critical role of complement activation. In this symposium we will discuss developments in the identification, differential diagnosis, and management of patients with TMA, with a particular focus on complement-related conditions. We will highlight the complexities of the differential diagnosis and how to navigate to a correct diagnosis, by guiding you through the evolution of clinical cases involving both the native and the transplanted kidney. We will also discuss the improved prognosis for patients with atypical haemolytic uraemic syndrome. Key to the successful management of TMA is being able to quickly and confidently make a differential diagnosis, and to rapidly initiate appropriate management strategies. Our interactive Q&A panel discussion aims to provide knowledge to aid the confident identification and management of patients with TMA.

On behalf of the faculty, I look forward to your participation in what will be an interesting and educational meeting.

Kind regards,

Manuel Praga
Chair
Professor of Medicine, Complutense University, Madrid, Spain.

Programme

Welcome and introduction: Recognizing the many faces of TMA
Manuel Praga
Madrid, Spain

Facing the future: rapid differential diagnosis of TMA
Christian Haas
Lübeck, Germany

The changing face of TMA diagnosis for the kidney transplant patient
Julien Zuber
Paris, France

Q&A panel discussion
All faculty

Please visit the Alexion booth in the industry exhibition area

INVITATION

TMA: multiple causes for a disease with 100 faces?

Sunday 22 May 2016, 13:30-15:00
Hall G - Level -2, Austria Centre Vienna

Chair: Dr Manuel Praga, Madrid, Spain

Please visit the Alexion booth in the industry exhibition area

Information presented at this industry-sponsored symposium is not necessarily endorsed by ERA-EDTA

Alexion Satellite Symposium at the 53rd Annual Scientific Meeting of the European Renal Association & European Dialysis and Transplant Association

Dear Colleagues,

It is our pleasure to invite you to attend the Alexion-sponsored satellite symposium at the 53rd European Renal Association–European Dialysis and Transplant Association congress.

TMA: multiple causes for a disease with 100 faces?

The prognosis for patients with thrombotic microangiopathy (TMA) has evolved with the understanding of the critical role of complement activation. In this symposium we will discuss developments in the identification, differential diagnosis, and management of patients with TMA, with a particular focus on complement-related conditions. We will highlight the complexities of the differential diagnosis and how to navigate to a correct diagnosis, by guiding you through the evolution of clinical cases involving both the native and the transplanted kidney. We will also discuss the improved prognosis for patients with atypical haemolytic uraemic syndrome. Key to the successful management of TMA is being able to quickly and confidently make a differential diagnosis, and to rapidly initiate appropriate management strategies. Our interactive Q&A panel discussion aims to provide knowledge to aid the confident identification and management of patients with TMA.

On behalf of the faculty, I look forward to your participation in what will be an interesting and educational meeting.

Kind regards,

Manuel Praga
Chair
Professor of Medicine, Complutense University, Madrid, Spain.

Programme

Welcome and introduction: Recognizing the many faces of TMA
Manuel Praga
Madrid, Spain

Facing the future: rapid differential diagnosis of TMA
Christian Haas
Lübeck, Germany

The changing face of TMA diagnosis for the kidney transplant patient
Julien Zuber
Paris, France

Q&A panel discussion
All faculty

Please visit the Alexion booth in the industry exhibition area

Information presented at this industry-sponsored symposium is not necessarily endorsed by ERA-EDTA
Chiesi Product Symposium

Advancements in immunosuppression: are all tacrolimus formulations the same?
Chaired by Prof. R. Oberbauer (Austria)

Control and optimization: the answer in PK
Prof. P. Marquet (France)

Management and clinical outcomes: the answer of the clinician
Prof. J. Pascual (Spain)

Lunch box will be available for the attendees.

Chiesi Farmaceutici S.p.A. was founded in 1935 and for decades has been a responsible partner for the medical community in both respiratory and specialty care areas. During these years of collaboration, the company has grown to be a global pharmaceutical company with products in respiratory (Foster®, Atimos®) and cardiovascular (Iperten®) areas, along with products in neonatology (Curosurf® and Peyona®) and in cystic fibrosis (Bramitob®).

Chiesi Group is now present in 26 affiliates worldwide, 6 research centres (Italy, UK, US, France, Sweden, Denmark) and more than 4,000 employees.

Thanks to its pipeline including some of the most promising molecules for the treatment of respiratory diseases and several rare diseases, Chiesi Group is confident of being able to continue its growth in the future, focusing equally on historical areas along with a strong interest on advanced therapies and new special care areas, such as transplantation.

The signature of the agreement with Veloxis Pharmaceuticals for the commercialisation of a novel formulation of tacrolimus was the first important sign of Chiesi commitment in this new area.
RARE DISEASES AND THE KIDNEY

UNEXPLAINED STORY AND COMPLEXITY OF FABRY DISEASE

Co-Chairs:
Prof. Gere Sunder-Plassmann (Austria)
Prof. Olivier Devuyst (Switzerland)

SYMPOSIUM
22 May 2016, 13:30 – 15:00
Lounge 3, Floor Level 1
At the 53rd ERA-EDTA Congress
Vienna, Austria
Lunch will be provided

AGENDA AND FACULTY

Welcome and Introduction
Prof. Gere Sunder-Plassmann (Austria)

Overview and Common Misdiagnosis of Rare Diseases in Nephrology
Prof. Olivier Devuyst (Switzerland)

Pathophysiology and Treatment of Fabry Disease: It’s Not as Simple as we May Think
Prof. Sandro Feriozzi (Italy)

How to Identify Fabry Disease Among Renal Patients: The Importance of Screening
Dr. Pablo Neumann (Argentina)

Q&A
IDS and NattoPharma invite you to attend our lunchtime symposium

**Date & time:** Sunday 22nd May 2016, 13:30 – 15:00
Lunch boxes will be served from 13:30
**Location:** Hall N, Austria Center Vienna, Vienna, Austria

The Infernal Triad: Matrix Gla-Protein, Vitamin K and Vascular Calcification

Vascular mineralisation is currently recognised as an actively regulated process where it was previously regarded as a passive end-stage process. The discovery that the vitamin K-dependent matrix Gla-protein (MGP) is a strong inhibitor of vascular calcification (VC) has opened novel avenues for risk assessment and monitoring disease progression. The distinguished international faculty presentations, led by Prof. Jürgen Floege and Prof. Etienne Cavalier, will focus on the burden of VC in chronic kidney disease (CKD) by Prof. Ziad Massy; review pivotal data supporting the linkage of VC and MGP by Dr. Leon Schurgers; essential roles of vitamin K2 and the need for a reliable measurement to quantify vitamin K status by Dr. Katarzyna Maresz.

**Programme**
- **Chair’s welcome and introduction**
  Prof. Dr. Jürgen Floege MD, FERA
  Director of the Department of Nephrology and Clinical Immunology
  Vice Dean of Medical School
  University of Aachen
  Germany

- **Vascular calcification in CKD patients**
  Prof. Ziad A. Massy, MD, PhD, FERA
  Chief, Division of Nephrology, Ambroise Paré Hospital
  Co-Director, INSERM U-1018
  Co-Director, CESP for UVSQ affairs
  CESP Team 5 (EpReC, Renal & Cardiovascular Epidemiology) UVSQ
  France

- **Vitamin K-dependent matrix Gla-Protein: a crucial switch to control ectopic mineralisation**
  Leon J. Schurgers, Ph.D.
  Associate Professor of Biochemistry
  Cardiovascular Research Institute Maastricht
  University Maastricht
  The Netherlands

- **Vitamin K2: an essential nutrient for cardiovascular health**
  Katarzyna Maresz, Ph.D.
  President of the International Science and Health Foundation
  Poland

- **Discussion**
  Prof. Dr. Jürgen Floege MD, FERA
  Prof. Etienne Cavalier, PhD. EuSpLM

- **Closing remarks**
  Prof Etienne Cavalier, PhD. EuSpLM
  Head, Department of Clinical Chemistry
  University of Liège, CHU Sart-Tilman
  Belgium
AN UNWAVERING COMMITMENT TO THE TASK AT HAND

HEPATITIS C IS A SERIOUS BURDEN THAT CAN HAVE DIRE CONSEQUENCES

According to the World Health Organization, the human cost of hepatitis C–related liver diseases is staggering: it claims the lives of approximately 500,000 people per year. However, recent advances in care have led many to believe that elimination of hepatitis C is possible. MSD remains committed more than ever to providing innovative solutions for advancement of chronic hepatitis C treatment and to working towards the ultimate goal of hepatitis C elimination.

Learn more about how MSD is addressing the task at hand by visiting Hall G, Level-2

References:


Treating secondary hyperparathyroidism with calcimimetics; new insights

Sunday, 22 May | 18:45 - 19:45
53rd ERA-EDTA Congress, Vienna | Austria
Austria Center Vienna, Hall K, Level-2

Chairman:
David Wheeler, London | United Kingdom

Programme:
18:30 Light buffet
18:45 Scientific programme starts
19:45 Scientific programme ends

Welcome and Introduction
David Wheeler
London | United Kingdom

Lessons learnt from the EVOLVE study
Jürgen Floege
Aachen | Germany

Etelcalcetide – A new injectable calcimimetic for the treatment of secondary hyperparathyroidism
Markus Ketteler
Coburg | Germany
Industry symposium
Sunday 22 May, 18:45 –19:45
Hall N, Level 1

Adverse cardiovascular events are the leading cause of death in patients with diabetic kidney disease (DKD). In this Bayer-sponsored symposium, a distinguished panel of experts will examine the link between renal and cardiovascular disease, and explore the benefits of current and emerging therapies in reducing cardiovascular risk in patients with DKD. Please join us for an informative and stimulating meeting.

Welcome and introduction
Chair: Hermann Haller (Germany)

Cardiovascular outcomes in patients with diabetic kidney disease: epidemiology and pathophysiology
Patrick Rossignol (France)

Emerging therapies for reducing renal and cardiovascular risk in patients with diabetic kidney disease
Peter Rossing (Denmark)

Summary and close
Hermann Haller

A light snack will be served from 18:45
We look forward to seeing you at the symposium
Optimizing the ESRD patient journey and RRT clinical-economic outcomes

Industry Symposium

13:30–15:00, Monday 23 May 2016
Hall D, Level -2 (brown level)
Austria Center Vienna

Lunch will be provided

Scientific Chair

Simon Davies, Stoke-on-Trent, UK

Faculty

Wim van Biesen, Ghent, Belgium
Eero Honkanen, Helsinki, Finland
Claus Peter Schmitt, Heidelberg, Germany

Agenda

Monday 23 May 2016
Program start time: 13:45
Program duration: one hour

Program

Introductions and welcome

Challenging the deadly paradigm of RRT modality transitions: an integrated approach to the patient ESRD journey

Doing the right thing at the right time: shared decision-making with RRT modality selection

The role of RPM and telemedicine in optimizing RRT modality outcomes and facilitating healthy transitions

Panel discussion and Q&A

Summary and close
ADPKD Treatment Update
An Otsuka-sponsored symposium

Bringing clarity to the evidence behind tolvaptan, identification of patients with rapidly progressing ADPKD and practical insights into the use of tolvaptan in the clinic

Monday 23 May
Lunchtime Symposium
13:30–14:45
Hall F, Austria Center Vienna
Chair: Professor Roser Torra

Lunch bags will be provided at the start of the symposium.

Programme

**Updated results of TEMPO 3:4**
13:50  Professor Vicente Torres,
Mayo Clinic College of Medicine,
Minnesota, USA

**How to identify patients with rapidly progressing ADPKD**
14:05  Professor Henrik Birn, Aarhus University,
Aarhus, Denmark

**Initiation and maintenance of tolvaptan: From theory into practice and early insights from the clinic**
14:15  Dr Roman-Ulrich Müller, University of Cologne, Cologne, Germany

**Panel discussion and Q&A session**
14:30  Led by Professor Roser Torra,
Autonomous University of Barcelona,
Barcelona, Spain

Prescribing information for tolvaptan can be found at https://www.jinarc.eu/docs/Jinarc_SmPC_May_2015.pdf

Date of preparation: March 2016
OPEL/0216/TOL/1004q
Dear Colleague,

It gives us great pleasure to welcome you to this Vifor Fresenius Medical Care Renal Pharma-sponsored symposium, entitled New insights into iron metabolism and deficiency.

This educational programme offers expert perspective from an internationally renowned faculty, who will first provide an overview of iron deficiency prevalence and the associated burden of disease in patients with chronic kidney disease (CKD). We then turn to what is currently known about the pathophysiology of iron deficiency in order to unravel its complexity before finally considering how to optimize diagnosis and treatment of iron deficiency in your patients. We will look at the most appropriate iron treatment, with a focus on the clinical benefits and potential risks of intravenous iron therapy.

This promises to be an engaging and informative educational session. We encourage you to submit your questions for the Q&A session by completing the question cards provided and handing them to an organizer during the symposium.

Sincerely,

Chair             Co-Chair
Professor Angel de Francisco          Professor Kai-Uwe Eckardt

New insights into iron metabolism and deficiency

Monday 23 May 2016
13:30–15:00
Hall B, Level 2
Austria Center Vienna

PROGRAMME

13:30      Lunch boxes will be provided

13:45–13:50      Chair’s introduction
Angel de Francisco (Santander, Spain)

13:50–14:10      ID prevalence in patients with CKD – a matter of definition?
Kai-Uwe Eckardt (Erlangen, Germany)

14:10–14:30      Iron pathophysiology – its complexity and our knowledge gaps
Tomas Ganz (Los Angeles, USA)

14:30–14:50      Diagnosing and treating ID/IDA – meeting your patient’s needs
Jolanta Małyszko (Bialystok, Poland)

14:50–15:00      Closing remarks and Q&A
Angel de Francisco
Management of Hyperkalemia: Challenges and Considerations in Patients with CKD

Invitation to a CME Symposium at the ERA-EDTA 2016 Congress, Vienna

Monday, May 23, 2016
13:30-15:00
Hall C, Level +2

Purpose of Activity
Hyperkalemia is a serious disturbance with increasing prevalence and a new treatment paradigm. Oral ion exchangers should have value not only to reduce the acute threat of hyperkalemia but also to achieve and maintain normal serum potassium levels enabling optimal use of renin-angiotensin-aldosterone system (RAAS) inhibitors for which there are proven clinical benefits. This broadens the range of eligible patients, lengthens the time on treatment and extends the focus to include the outpatient arena. Although as a general rule all instances of hyperkalemia should be deemed actionable, the nature and urgency of appropriate actions depend heavily on clinical judgment and are influenced by the initial point of care. The purpose of this presentation is to bring forward some of the considerations that inform clinical judgments essential to the evaluation and management of hyperkalemia in the outpatient CKD arena. Program content includes a review of the cellular mechanisms that normally ensure potassium homeostasis, how these are affected by RAAS inhibitors, hyperkalemic risk assessment based on clinical trials, and characteristics of the ideal, current and emerging oral ion exchangers.

Educational Objectives
After completing this activity, the participant should be better able to:
1: Review the mechanisms that regulate potassium balance, and how they are affected by RAAS inhibition.
2: Describe the pathophysiology of hyperkalemia as affected by underlying conditions that modify clinical outcomes.
3: Identify considerations that clarify the urgency of actionable degrees of hyperkalemia based on information from clinical trials.
4: Present information on emerging oral ion exchangers and how they may affect current practices.

Target Audience
This activity has been designed to meet the educational needs of Nephrology professionals involved in the care of patients with kidney disease.

This symposium is funded by AstraZeneca

This activity is jointly provided by SynAptiv and The Med Ed Group, Inc.
SATELLITE SYMPOSIUM

UNKNOWN UNKNOWNS IN CHRONIC KIDNEY DISEASE

MONDAY 23rd MAY, 13:30 – 15:00
ROOM: HALL G (LEVEL -2)

CHAIR: PROF. ALBERTO ORTIZ

WHAT IS AN UNKNOWN UNKNOWN IN CHRONIC KIDNEY DISEASE?
PREVALENCE OF UNDIAGNOSED PRIMARY AND SECONDARY CAUSES OF CKD
PROF. GIUSEPPE CASTELLANO

UTILITY OF RENAL BIOPSIES IN DIAGNOSIS AND TREATMENT OF SECONDARY AND RARE CAUSES OF CKD
PROF. ALBERTO ORTIZ

KDIGO CONFERENCE ON FABRY NEPHROPATHY: MANAGEMENT OF RARE CAUSES OF CKD
DR. BOJAN VUJKOVAC

LUNCH TO BE PROVIDED

SANOFI GENZYME
Program Overview

This state-of-the-art satellite symposium will bring together a panel of international tuberous sclerosis complex (TSC) experts to discuss the identification and management of TSC-related renal manifestations, review current long-term data on the role of mTOR inhibition in patients with TSC, and provide renal specialists with an overview of management strategies to help preserve renal function. Through a series of brief evidence-based presentations, the audience will gain an increased knowledge and familiarity of renal complications associated with TSC and current treatment approaches. Throughout the 60-minute symposium, questions will be posed to the audience to allow for a broader understanding of preserving renal function in patients with TSC. The audience will also be able to submit questions to the panel to support further discussion and engagement. The chair will highlight recommendations for best practices in the management of TSC-related renal manifestations, and a short series of interactive questions will help gauge audience learning, assess remaining unmet needs, and reinforce key points.

Program Objectives

• Raise awareness of the importance of identifying and treating TSC-related renal manifestations
• Provide the most current data on everolimus and the role of mTOR inhibition to renal specialists, highlighting longer-term data
• Deliver key TSC- and mTOR-related educational expertise to renal specialists to optimize the management of TSC-related renal manifestations

This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities. This program and/or material was developed for use outside of the US, intended for non-US healthcare professionals, and is to be used in accordance with local laws and regulations.
HALL M, LEVEL 1

PROGRAM
Chairmen: Pr. Eric Goffin (Belgium) and Dr. Maxence Ficheux (France)

“HOME HD: HOW IT LOOKS & HOW IT WORKS”
Dr. Shashidhar Cherukuri (United Kingdom)

“THE SUITABLE PATIENT & PRESCRIBING HOME HD”
Dr. Natalie Borman (United Kingdom)

“THE EUROPEAN EXPERIENCE: CLINICAL OUTCOMES FROM THE KIHONDEy COHORT”
Dr. Per Westerlund (Sweden)

“PATIENT EXPERIENCE: WHAT ARE THE SUCCESS FACTORS”
Dr. Hafedh Fessi (France)

Taking place during the 53rd ERA-EDTA Congress

MONDAY • MAY 23, 2016 • 13:30 – 15:00
VIENNA, AUSTRIA

challenges to improve hemodialysis outcomes: are frequent and home the answers?
We are delighted to invite you to participate in the satellite symposium **Rare Renal Diseases Are Growing Up**, An eminent pan-European panel of experts will offer insights into the contemporary management and care of patients with rare renal tubulopathies.

We sincerely hope you can join us in what promises to be a very productive and impactful meeting.

**Monday, May 23rd, 2016**  13:30 - 15:00
Hall N - Level 1

- 13:45 Chairman’s welcome  
  Prof. Rainer Oberbauer, Vienna
- 13:50 Cystinosis vs CKD: Growth and neurocognitive development in childhood  
  Dieter Haffner, Hannover
- 14:05 Managing the Adolescent Patient  
  Larissa Kerecuk, Birmingham
- 14:20 Cystinosis in Adults ; An Emerging Population  
  Albane Boidin-Sartorus, Paris
- 14:30 Discussion
- 14:40 Closing remarks

Lunch boxes will be provided

**Visit us at the Raptor Pharmaceuticals Booth**  
Booth No. 2.260

---

**THANK YOU for attending our Satellite Symposium**

We are delighted to invite you to participate in the satellite symposium **Rare Renal Diseases Are Growing Up**, An eminent pan-European panel of experts will offer insights into the contemporary management and care of patients with rare renal tubulopathies.

We sincerely hope you can join us in what promises to be a very productive and impactful meeting.

**Monday, May 23rd, 2016**  13:30 - 15:00
Hall N - Level 1

- 13:45 Chairman’s welcome  
  Prof. Rainer Oberbauer, Vienna
- 13:50 Cystinosis vs CKD: Growth and neurocognitive development in childhood  
  Dieter Haffner, Hannover
- 14:05 Managing the Adolescent Patient  
  Larissa Kerecuk, Birmingham
- 14:20 Cystinosis in Adults ; An Emerging Population  
  Albane Boidin-Sartorus, Paris
- 14:30 Discussion
- 14:40 Closing remarks

Lunch boxes will be provided

**Visit us at the Raptor Pharmaceuticals Booth**  
Booth No. 2.260
Carnitine is a small compound, which plays a crucial role in human metabolism and is derived from exogenous dietary sources but also synthesized endogenously. In the first lecture, the current state of knowledge with respect to carnitine in human health and disease with particular emphasis on the various genetic metabolic diseases in which carnitine is involved, will be discussed.

The disturbance in carnitine homeostasis associated with haemodialysis treatment has been well described, with numerous studies demonstrating a significant and dramatic reduction in endogenous blood and tissue L-carnitine concentrations. This will be the topic of the second presentation.

For the first time, research work has conducted a randomised, double-blind, placebo-controlled to assess the efficacy of intravenous L-carnitine supplementation as an adjunct for the treatment of renal anaemia in chronic haemodialysis patients hyporesponsive to ESA treatment. It will be discussed the effectiveness of L-carnitine supplementation normalizing the carnitine pool and increasing the erythrocyte carnitine palmitoyltransferase activity with consequential increased red blood cell survival.

The last, but not least, presentation will focus on the records review of patients with acute kidney injury receiving continuous renal replacement therapy (CRRT) at Children’s National Health System between 2011 and 2014 for total carnitine (TC), free carnitine (FC) levels, and survival outcomes.

In light of the high rate of carnitine deficiency in children receiving CRRT, and high risk of morbidity and mortality in this population, the data of an ongoing randomized, prospective, controlled clinical trial to investigate the effects of carnitine supplementation on myocardial function in children receiving CRRT (www.clinicaltrials.gov, NCT01941823) will be disclosed.

References:

Next Congresses

Cristina Ortiz, "Moving forward", 2014, mixed technique, 120 cm x 70 cm, from the exhibition "Aspirations"